CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. In fiscal year 2021, the company had revenues of $915 million, with net income of $378 million. By the end of the same year, the number of employees stood at 473. As of December 2021, the company had a market capitalization of over $6 billion. CRISPR Therapeutics' investors include German chemical company Bayer. The company operates R&D in Cambridge, Massachusetts.
